No Data
Wuhan Hiteck Biological Pharma (300683.SZ) has obtained the pharmaceutical registration certificate for ketamine hydrochloride injection.
On November 6, Guolonghui reported that Wuhan Hiteck Biological Pharma (300683.SZ) announced that the company recently received the 'Pharmaceutical Registration Certificate' approved and issued by the National Medical Products Administration for the injection of ketoprofen. Ketoprofen injection is suitable for peripheral arterial disease (intermittent claudication or rest pain), inner ear circulatory disorders, and is a national medical insurance category B variety. Ketoprofen and its metabolites improve blood rheological properties by reducing blood viscosity, increasing blood flow to affected microcirculation in patients with chronic peripheral arterial disease, and enhancing tissue oxygenation. It dose-dependently improves blood rheology and can reduce blood viscosity.
wuhan hiteck biological pharma (300683.SZ): There is currently no use or research on AI.
Gelonghui November 4th, wuhan hiteck biological pharma (300683.SZ) stated on the investor interaction platform that the company currently has no use or research in the AI field, and will continue to monitor the application and development of AI technology in the biomedical field.
Haite Biotech: Report for the third quarter of 2024
Wuhan Hiteck Biological Pharma (300683.SZ): Obtains the pharmaceutical registration certificate for injectable esomeprazole sodium.
On September 11, Gelonghui reported that Wuhan Hiteck Biological Pharma (300683.SZ) announced that the company recently received the "Drug Registration Certificate" for injection of esomeprazole sodium issued by the National Medical Products Administration. Esomeprazole, also known as esomeprazole, is the single left-handed isomer of omeprazole. Both belong to proton pump inhibitors, which can effectively inhibit the secretion of gastric acid, and are clinically used to treat gastroesophageal reflux disease, erosive esophagitis, etc. This drug is one of the most successful examples of isomer development. Compared with the first generation omeprazole, it has a stronger effect in inhibiting gastric acid and fewer adverse reactions. This drug was originally developed by AstraZeneca.
Haite Biotech: 2024 Semi-Annual Report Summary
Haite Biotech: 2024 Semi-Annual Report
No Data
No Data